Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dividend investing for retirement -- Ignore unavailable to you. Want to Upgrade?

To: E_K_S who wrote (33179)	10/30/2020 8:29:13 AM
From: Ditchdigger	1 Recommendation Recommended By Kip S Read Replies (1) \| Respond to of 34328

History repeats :), They've raised it 10% every year I've held it so far. I still think Rinvoq could do very well for them, off setting Humira declines.

To: E_K_S who wrote (33179)	10/30/2020 9:31:11 AM
From: CusterInvestor	5 Recommendations Recommended By B.K.Myers Ditchdigger E_K_S KEN2CWL Mannie Respond to of 34328

Even better, they raised guidance: AbbVie (NYSE: ABBV): Q3 Non-GAAP EPS of $2.83 beats by $0.06; GAAP EPS of $1.29 misses by $0.13. Revenue of $12.9B (+52.1% Y/Y) beats by $190M. Non-GAAP gross margin of 81.7%. Non-GAAP operating margin 48.8%. FY20 Guidance: Raised its GAAP EPS guidance from $4.12 to $4.22 to $3.89 to $3.91, which includes the results of Allergan from May 8, 2020 through December 31, 2020. Raised its adjusted EPS guidance from $10.35 to $10.45 to $10.47 to $10.49, which includes the results of Allergan from May 8, 2020 through December 31, 2020, representing annualized net accretion from the Allergan transaction of 12 percent. The combined company's adjusted EPS guidance excludes $6.58 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.